In the 9 years since the publication of our 2011 review of targeted treatment of thyroid cancer with multikinase inhibitors, much has changed in the landscape of this heterogeneous disease. New multikinase and selective inhibitor treatments for medullary thyroid cancer, radioiodine-refractory thyroid ...
Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. Expert Rev Anticancer Ther 2010;10: 635-645.Bukowski RM (2010) Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. Expert Rev Anticancer Ther 10:635-645...
inhibitortargetedtherapyAlthough patients with thyroid cancer generally fare well, there is a subset for which this is not necessarily true. Progress in ... Steven,P,Weitzman,... - 《Cancer Management & Research》 被引量: 23发表: 2015年 Treatment strategies for radioactive iodine-refractory diffe...
Co-targeted treatment approach was effective in reducing proliferation of prostate cancer cells. LNCaP, C4-2 and C4-2B cells were cultured and treated for 72 h using increasing concentrations of PIM inhibitor AZD-1208 or PI3K/mTOR inhibitor BEZ235 alone, a combination of AZD-1208 and BEZ235, ...
A novel, EGFR-targeted nanomedicine has been developed in the current study. Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100 nm were loaded with the multikinase inhibitor 17864-L-x-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of alb...
The purpose of this paper is to review the development of targeted agents for thyroid malignancy, with a special focus on lenvatinib, a multikinase inhibitor.StjepanovicDepartmentNedaDepartmentCapdevilaDepartmentJaumeDepartmentEBSCO_AspBiologics Targets & Therapy...
Targeted therapies by means of compounds that inhibit multiple target molecules represent a new perspective in the treatment and prevention of cancer. Vandetanib (Zactima) is an orally active, selective inhibitor of VEGFR-2 (vascular endothelial growth factor receptor-2) receptor tyrosine kinase that ...
This study is to determine whether autophagy is activated by a novel multikinase inhibitor linifanib, thereby impairing the sensitivity of hepatocellular carcinoma (HCC) cells to this targeted therapy. Here, we found that linifanib induced a high level of autophagy in HCC cells, which was ...
Background Targeted therapy approaches have been successfully introduced into the treatment of several cancers. The multikinase inhibitor Sorafenib has antitumor activity in solid tumors and its effects on acute lymphoblastic leukemia (ALL) cells are still unclear. Methods ALL cell lines (SEM, RS4;11...
Update on multikinase inhibitor therapy for differentiated thyroid cancerMultikinase inhibitorsTyrosine kinase inhibitorsDifferentiated thyroid cancerCancer therapyLenvatinibSorafenibCurative therapies for radioiodine-refractory differentiated thyroid cancer remain lacking. However, oral multikinase inhibitors often allow ...